Motley Fool warns against chasing biotech rally amid hantavirus outbreak

The Motley Fool has published an analysis advising investors against purchasing shares in pharmaceutical and biotech companies experiencing a market rally following a hantavirus outbreak on a cruise ship. The publication argues that the virus is unlikely to trigger a global pandemic comparable to COVID-19 due to limited person-to-person transmission. Furthermore, the analysis highlights the historical unpredictability of vaccine development success, noting that major firms such as Sanofi and Merck did not dominate the COVID-19 vaccine market. It also points out that even successful developers like Pfizer and Moderna have underperformed the S&P 500 since 2020. Consequently, the author recommends broad index ETFs as a safer long-term strategy. While acknowledging Moderna’s work on a hantavirus vaccine and Pfizer’s pipeline progress, the Motley Fool’s Stock Advisor team does not currently include either company in its recommended stock list.

The outbreak has sparked a rally in the sector, with some investors anticipating financial rewards for firms that develop effective vaccines. However, the Motley Fool contends that the hantavirus is primarily transmitted via contact with infected rodents rather than through respiratory droplets between people. Although a variant known as the Andes virus can spread between humans, health officials note its transmission rate is significantly lower than that of COVID-19. This limited person-to-person spread suggests the virus is easier to contain, potentially resulting in a much smaller market for hantavirus vaccines than the pandemic-era demand seen previously.

Even in a worst-case scenario where the outbreak escalates into a global health crisis, the publication argues that identifying the successful vaccine developers remains highly unpredictable. The COVID-19 experience demonstrated that many companies, including small biotechs and major pharmaceutical giants like Sanofi and Merck, failed to develop competitive vaccines in a timely manner. The fact that established vaccine makers did not necessarily dominate the market illustrates that investing in well-known firms does not guarantee success, as the actual winners may be under-the-radar corporations.

Furthermore, the analysis points out that even if an investor successfully identifies a company that develops a hantavirus vaccine, market-beating returns are not assured. Data provided shows that Pfizer, Moderna, BioNTech, and Novavax, which dominated the COVID-19 vaccine market at its peak, have underperformed the S&P 500 since January 2020. Pfizer, in particular, has underperformed by a substantial margin. The Motley Fool suggests that investors focused on the long term should avoid picking individual stocks in this sector and instead consider investing in an ETF that tracks major indexes such as the S&P 500 or the Nasdaq.

While the Motley Fool’s Stock Advisor team does not currently recommend Moderna or Pfizer as part of its top 10 best stocks, it acknowledges their broader pipeline strengths. Moderna is noted for its work on the mRNA-4157 cancer vaccine and its advanced mRNA platform, while Pfizer is highlighted for replenishing its pipeline with pivotal trials starting in 2026. However, the publication contrasts these individual prospects with the historical performance of its own recommendations, citing that a $1,000 investment in Netflix or Nvidia at the time of their inclusion in the Stock Advisor list would have yielded significantly higher returns than the broader market.